PUBMED FOR HANDHELDS

Journal Abstract Search


403 related items for PubMed ID: 31335316

  • 1. Long term tapering versus standard prednisolone treatment for first episode of childhood nephrotic syndrome: phase III randomised controlled trial and economic evaluation.
    Webb NJA, Woolley RL, Lambe T, Frew E, Brettell EA, Barsoum EN, Trompeter RS, Cummins C, Deeks JJ, Wheatley K, Ives NJ, PREDNOS Collaborative Group.
    BMJ; 2019 May 23; 365():l1800. PubMed ID: 31335316
    [Abstract] [Full Text] [Related]

  • 2. Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT.
    Webb NJ, Woolley RL, Lambe T, Frew E, Brettell EA, Barsoum EN, Trompeter RS, Cummins C, Wheatley K, Ives NJ.
    Health Technol Assess; 2019 May 23; 23(26):1-108. PubMed ID: 31156083
    [Abstract] [Full Text] [Related]

  • 3. Daily low-dose prednisolone to prevent relapse of steroid-sensitive nephrotic syndrome in children with an upper respiratory tract infection: PREDNOS2 RCT.
    Christian MT, Webb NJ, Woolley RL, Afentou N, Mehta S, Frew E, Brettell EA, Khan AR, Milford DV, Bockenhauer D, Saleem MA, Hall AS, Koziell A, Maxwell H, Hegde S, Finlay ER, Gilbert RD, Jones C, McKeever K, Cook W, Ives N.
    Health Technol Assess; 2022 Jan 23; 26(3):1-94. PubMed ID: 35060851
    [Abstract] [Full Text] [Related]

  • 4. Short course daily prednisolone therapy during an upper respiratory tract infection in children with relapsing steroid-sensitive nephrotic syndrome (PREDNOS 2): protocol for a randomised controlled trial.
    Webb NJ, Frew E, Brettell EA, Milford DV, Bockenhauer D, Saleem MA, Christian M, Hall AS, Koziell A, Maxwell H, Hegde S, Finlay ER, Gilbert RD, Booth J, Jones C, McKeever K, Cook W, Ives NJ, PREDNOS 2 study group.
    Trials; 2014 Apr 27; 15():147. PubMed ID: 24767719
    [Abstract] [Full Text] [Related]

  • 5. REducing STEroids in Relapsing Nephrotic syndrome: the RESTERN study- protocol of a national, double-blind, randomised, placebo-controlled, non-inferiority intervention study.
    Schijvens AM, Dorresteijn EM, Roeleveld N, Ter Heine R, van Wijk JAE, Bouts AHM, Keijzer-Veen MG, van de Kar NCAJ, van den Heuvel LPWJ, Schreuder MF.
    BMJ Open; 2017 Sep 27; 7(9):e018148. PubMed ID: 28963315
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of low-dose daily versus alternate-day prednisolone in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial.
    Yadav M, Sinha A, Khandelwal P, Hari P, Bagga A.
    Pediatr Nephrol; 2019 May 27; 34(5):829-835. PubMed ID: 30194663
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of Daily Low-Dose Prednisolone During Upper Respiratory Tract Infection to Prevent Relapse in Children With Relapsing Steroid-Sensitive Nephrotic Syndrome: The PREDNOS 2 Randomized Clinical Trial.
    Christian MT, Webb NJA, Mehta S, Woolley RL, Afentou N, Frew E, Brettell EA, Khan AR, Milford DV, Bockenhauer D, Saleem MA, Hall AS, Koziell A, Maxwell H, Hegde S, Prajapati H, Gilbert RD, Jones C, McKeever K, Cook W, Ives N.
    JAMA Pediatr; 2022 Mar 01; 176(3):236-243. PubMed ID: 34928294
    [Abstract] [Full Text] [Related]

  • 8. Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroid-sensitive nephrotic syndrome.
    Sinha A, Saha A, Kumar M, Sharma S, Afzal K, Mehta A, Kalaivani M, Hari P, Bagga A.
    Kidney Int; 2015 Jan 01; 87(1):217-24. PubMed ID: 25029428
    [Abstract] [Full Text] [Related]

  • 9. Prevention of relapses with levamisole as adjuvant therapy in children with a first episode of idiopathic nephrotic syndrome: study protocol for a double blind, randomised placebo-controlled trial (the LEARNS study).
    Veltkamp F, Khan DH, Reefman C, Veissi S, van Oers HA, Levtchenko E, Mathôt RAA, Florquin S, van Wijk JAE, Schreuder MF, Haverman L, Bouts AHM.
    BMJ Open; 2019 Aug 01; 9(8):e027011. PubMed ID: 31375606
    [Abstract] [Full Text] [Related]

  • 10. Short courses of daily prednisolone during upper respiratory tract infections reduce relapse frequency in childhood nephrotic syndrome.
    Abeyagunawardena AS, Thalgahagoda RS, Dissanayake PV, Abeyagunawardena S, Illangasekera YA, Karunadasa UI, Trompeter RS.
    Pediatr Nephrol; 2017 Aug 01; 32(8):1377-1382. PubMed ID: 28341877
    [Abstract] [Full Text] [Related]

  • 11. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.
    Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, Ohashi Y, Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group.
    Lancet; 2014 Oct 04; 384(9950):1273-81. PubMed ID: 24965823
    [Abstract] [Full Text] [Related]

  • 12. Oral steroids for hearing loss associated with otitis media with effusion in children aged 2-8 years: the OSTRICH RCT.
    Francis NA, Waldron CA, Cannings-John R, Thomas-Jones E, Winfield T, Shepherd V, Harris D, Hood K, Fitzsimmons D, Roberts A, Powell CV, Gal M, Jones S, Butler CC.
    Health Technol Assess; 2018 Nov 04; 22(61):1-114. PubMed ID: 30407151
    [Abstract] [Full Text] [Related]

  • 13. Study protocol: high-dose mizoribine with prednisolone therapy in short-term relapsing steroid-sensitive nephrotic syndrome to prevent frequent relapse (JSKDC05 trial).
    Hama T, Nakanishi K, Ishikura K, Ito S, Nakamura H, Sako M, Saito-Oba M, Nozu K, Shima Y, Iijima K, Yoshikawa N, Japanese Study Group of Kidney Disease in Children (JSKDC).
    BMC Nephrol; 2018 Sep 10; 19(1):223. PubMed ID: 30200895
    [Abstract] [Full Text] [Related]

  • 14. Short-Duration Prednisolone in Children with Nephrotic Syndrome Relapse: A Noninferiority Randomized Controlled Trial.
    Kainth D, Hari P, Sinha A, Pandey S, Bagga A.
    Clin J Am Soc Nephrol; 2021 Feb 08; 16(2):225-232. PubMed ID: 33478976
    [Abstract] [Full Text] [Related]

  • 15. Corticosteroid therapy for nephrotic syndrome in children.
    Hodson EM, Knight JF, Willis NS, Craig JC.
    Cochrane Database Syst Rev; 2003 Feb 08; (1):CD001533. PubMed ID: 12535410
    [Abstract] [Full Text] [Related]

  • 16. Long versus standard initial prednisolone therapy in children with idiopathic nephrotic syndrome.
    Paul SK, Muinuddin G, Jahan S, Begum A, Rahman MH, Hossain MM.
    Mymensingh Med J; 2014 Apr 08; 23(2):261-7. PubMed ID: 24858152
    [Abstract] [Full Text] [Related]

  • 17. Corticosteroid therapy for nephrotic syndrome in children.
    Hodson EM, Knight JF, Willis NS, Craig JC.
    Cochrane Database Syst Rev; 2004 Apr 08; (2):CD001533. PubMed ID: 15106158
    [Abstract] [Full Text] [Related]

  • 18. Corticosteroid therapy for nephrotic syndrome in children.
    Hahn D, Hodson EM, Willis NS, Craig JC.
    Cochrane Database Syst Rev; 2015 Mar 18; 2015(3):CD001533. PubMed ID: 25785660
    [Abstract] [Full Text] [Related]

  • 19. Single vs split dose of prednisolone in the treatment of relapses of childhood nephrotic syndrome.
    Weerasooriya WALK, Abeyagunawardena AS, Thalgahagoda RS.
    Eur J Pediatr; 2023 Apr 18; 182(4):1741-1747. PubMed ID: 36757496
    [Abstract] [Full Text] [Related]

  • 20. Long-term efficacy and safety of common steroid-sparing agents in idiopathic nephrotic children.
    Basu B, Babu BG, Mahapatra TK.
    Clin Exp Nephrol; 2017 Feb 18; 21(1):143-151. PubMed ID: 27108294
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 21.